Navigation Links
STAAR Surgical Reports 33% Third Quarter Revenue Growth
Date:10/28/2008

."

"We reduced operating cash burn by approximately 29% compared to the third quarter of last year and reduced U.S. operational spending by 20% as well," added Mr. Caldwell. "During the quarter our team identified future opportunities to reduce spending and build margins within our international operations. As a result, international operating costs were down 11% compared to the second quarter of this year. In addition, we remain confident in our ability to achieve our operating expense targets in Japan. Finally, our plan is to generate overall operating income in the current fourth quarter," Mr. Caldwell continued.

In addition, the Company earlier in the month completed all the clinical data work for the re-submission of its application with the FDA for the Visian Toric ICL, a toric implantable Collamer(R) lens designed to treat both nearsightedness and astigmatism. "We are pleased that the certified clinical trial module resulting from this effort confirmed the scientific validity and integrity of the data and the excellent clinical results of this product. Beyond that result, the comprehensive reexamination of both study data and our procedures as a sponsor of clinical studies has provided an opportunity to improve and enhance our ability to oversee clinical projects in the future," said Mr. Caldwell. "The task required the coordination and cooperation of several departments within the Company along with the third party audit firm. These efforts were led by John Santos, our acting V.P. of Clinical Affairs, who deserves special recognition for this successful completion."

Financial Highlights for the Third Quarter and Nine Months Ended September 26, 2008

Total product sales in the quarter were $18.1 million which is the highest level of sales for any third quarter achieved by the Company in its 26 years of operation. These sales represented a 33% increase over the $13.6 million reported for the third quarter of 2007. The increase in sal
'/>"/>

SOURCE STAAR Surgical Company
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine news :

1. STAAR Surgical to Present at the Noble Financial Equity Conference
2. STAAR Surgicals Collamer(R) IOL and Elastimide(R) IOL Each Recognized with New Technology Intraocular Lens Classification
3. STAAR Surgicals LASIK Alternative Expands U.S. Market Gains
4. STAAR Surgical Reports Solid First Quarter Progress
5. STAAR Surgical Announces First Quarter 2008 Earnings Release Date and Conference Call
6. STAAR Surgical Plans Major Presence at ASCRS
7. STAAR Surgical Reports Fourth Quarter and Year End Results
8. STAAR Surgicals Visian ICL Procedure Performed Live on NBCs Today show
9. STAAR Surgical Announces Fourth Quarter and Full Year 2007 Earnings Release Date and Conference Call
10. STAAR Surgical to Present at the Tenth Annual Needham Growth Conference
11. STAAR Surgical Completes $5M Debt Financing for Purchase of Japanese Joint Venture
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2009)... wrong with being single, myth , , SATURDAY, Dec. 5 (HealthDay ... 40th birthday without ever tying the knot, since research has ... folks. And, um, isn,t there something wrong with those who ... new study looking at psychological measures shows that never-married people ...
(Date:12/5/2009)... today announced the launch of International Solutions, an innovative new international ... its UK equivalent. In addition to offering customers the flexibility to ... needs and budgets, International Solutions enables customers to tailor their benefits ... , ...
(Date:12/5/2009)... to do everything from growing mushrooms, making wine to keeping prisoners in ... ... that your wine, water and vegetables would have come from Wind Turbines? ... turbines, for industry end users, not wind farms. "Using a technology ...
(Date:12/4/2009)... YORK, Dec. 4 Care Investment Trust Inc. (NYSE: ... its Board of Directors has declared a dividend of $0.17 per ... 22, 2009 to common shareholders of record on December 14, 2009. ... Care Investment Trust Inc. is a real estate investment and finance ...
(Date:12/4/2009)... Dec. 4 Medithrive, Inc. has won the Patient,s ... Bay Area by popular vote conducted by the online ... operation, the SF Bay community has selected Medithrive as ... ,, The rapid rise and popularity of Medithrive confirms ...
Breaking Medicine News(10 mins):Health News:Never Married, Over 40, Well-Adjusted 2Health News:Never Married, Over 40, Well-Adjusted 3Health News:AVIVA's Private Health Insurance Products Solutions Go International 2Health News:Distributor Announces New Applications for Wind Turbines 2Health News:Distributor Announces New Applications for Wind Turbines 3Health News:Care Investment Trust Inc. Declares Quarterly Dividend of $0.17 Per Share 2
... Pharmacyclics,Inc. (Nasdaq: PCYC ) today announced that ... and Drug Administration (FDA) for the company,s,new drug application ... non-small cell lung cancer (NSCLC) patients with brain,metastases. The ... brain,radiation therapy (WBRT) was filed with the FDA in ...
... Corp. ("Echo" or the "Company") (OTC Bulletin Board: ... meeting of stockholders today,that the polls will remain ... vote on the proposed merger transaction with XLNT,Veterinary ... forth in the,proxy statement/prospectus previously mailed to Echo ...
... Inc. (Nasdaq:,BIOD) today announced that Dr. Solomon Steiner, Chairman ... the 26th Annual JPMorgan Healthcare,Conference on Monday, January 7, ... Healthcare Conference will be held January 7-10, 2008, at,the ... Interested parties may access a link to a live ...
... HORSHAM, Pa. and KENILWORTH, N.J., Dec. 21 ... SGP ) today announced,they have revised their ... distribution of both REMICADE(R),(infliximab), an anti-tumor necrosis ... and golimumab, Centocor,s next-generation,human, anti-TNF alpha therapy, ...
... Alta Bates Summit Medical Center receives shipment milestone ... SET and Masimo Rainbow SET technologies, IRVINE, ... of Pulse CO-Oximetry and Read-Through Motion and Low,Perfusion ... shipped its,500,000th Masimo SET bedside pulse oximeter (excluding ...
... ensure consumers, interests are considered, protected, HARRISBURG, Pa., ... protected, acting Insurance Commissioner Joel,Ario today announced that the ... of its review of the proposed consolidation of,Independence Blue ... to see that consumers would be protected in,any transaction ...
Other Medicine News:Health News:Pharmacyclics Receives Non-Approvable Letter from the FDA for Xcytrin for the Treatment of Lung Cancer Brain Metastases 2Health News:Pharmacyclics Receives Non-Approvable Letter from the FDA for Xcytrin for the Treatment of Lung Cancer Brain Metastases 3Health News:Echo Healthcare Extends Stockholder Vote on Proposed Merger With XLNT Veterinary Care to December 28, 2007 2Health News:Echo Healthcare Extends Stockholder Vote on Proposed Merger With XLNT Veterinary Care to December 28, 2007 3Health News:Echo Healthcare Extends Stockholder Vote on Proposed Merger With XLNT Veterinary Care to December 28, 2007 4Health News:Echo Healthcare Extends Stockholder Vote on Proposed Merger With XLNT Veterinary Care to December 28, 2007 5Health News:Biodel Inc. to Present at 26th Annual JPMorgan Healthcare Conference on January 7th, 2008 2Health News:Biodel Inc. to Present at 26th Annual JPMorgan Healthcare Conference on January 7th, 2008 3Health News:Centocor, Schering-Plough Revise Agreement Covering REMICADE, Golimumab 2Health News:Centocor, Schering-Plough Revise Agreement Covering REMICADE, Golimumab 3Health News:Centocor, Schering-Plough Revise Agreement Covering REMICADE, Golimumab 4Health News:Masimo Celebrates 500,000th Pulse Oximeter Shipped 2Health News:Masimo Celebrates 500,000th Pulse Oximeter Shipped 3Health News:Masimo Celebrates 500,000th Pulse Oximeter Shipped 4Health News:Masimo Celebrates 500,000th Pulse Oximeter Shipped 5Health News:Insurance Department Will Hold Public Hearings on Proposed Consolidation of Highmark, Independence Blue Cross 2
(Date:12/4/2009)... U.S. Food and Drug Administration (FDA) today approved Zyprexa® ... treatment of schizophrenia and manic or mixed episodes associated ... old. ,, The updated Zyprexa label states that ... weight gain and hyperlipidemia in adolescents compared to adults ...
(Date:12/4/2009)... ,, PHILADELPHIA, Dec. 4 Teamster members employed by ... hard at work educating the public about the unfair ... Philadelphia,s blood supply at risk. More than 100 ... line yesterday when their issues were ignored by their ...
(Date:12/4/2009)... Inc. (OTC Bulletin Board: OXBT) today announced that the ... II-b, dose escalation, clinical trial in Switzerland for use ... is the Company,s perfluorocarbon (PFC) therapeutic oxygen carrier. ,, ... outcome of patients with severe TBI. We hope to ...
Breaking Medicine Technology:FDA Approves Lilly's Zyprexa for Two Adolescent Indications 2FDA Approves Lilly's Zyprexa for Two Adolescent Indications 3FDA Approves Lilly's Zyprexa for Two Adolescent Indications 4FDA Approves Lilly's Zyprexa for Two Adolescent Indications 5FDA Approves Lilly's Zyprexa for Two Adolescent Indications 6FDA Approves Lilly's Zyprexa for Two Adolescent Indications 7Striking Red Cross Workers Raise Public Awareness of Unsafe Working Conditions 2Oxygen Biotherapeutics, Inc. Enrolls First Patient in Traumatic Brain Injury Clinical Trial in Switzerland 2Science study 3A Teacher participation in Columbia program improves student achievement in science 59663 1Science study 3A Teacher participation in Columbia program improves student achievement in science 59663 2Science study 3A Teacher participation in Columbia program improves student achievement in science 59663 3Science study 3A Teacher participation in Columbia program improves student achievement in science 59663 4Yerkes researchers present at 39th Annual Society for Neuroscience Conference 59660 1Yerkes researchers present at 39th Annual Society for Neuroscience Conference 59660 2Yerkes researchers present at 39th Annual Society for Neuroscience Conference 59660 3Yerkes researchers present at 39th Annual Society for Neuroscience Conference 59660 4Yerkes researchers present at 39th Annual Society for Neuroscience Conference 59660 5Fish vision discovery makes waves in natural selection 10401 1Fish vision discovery makes waves in natural selection 10401 2Fish vision discovery makes waves in natural selection 10401 3
... 10, 2007 - Inotek,Pharmaceuticals Corporation announced today the ... showing that the,administration of a poly(ADP-Ribose) polymerase (PARP) ... of certain brain,cells following a stroke. PARP is ... DNA via the activation and recruitment of DNA,repair ...
... Unite to Help Educate on Good,Diabetes Management and ... Problems, SEATTLE, April 10, 2007 /PRNewswire/ -- A ... type 2 diabetes,complications shows that an estimated three ... diabetes have at least one of the other,serious ...
Other Medicine Technology:Inotek Pharmaceuticals Announces Publication of Animal Data from,Study of PARP Inhibition as Potential Preventative of Brain Injury,Following Stroke 2Inotek Pharmaceuticals Announces Publication of Animal Data from,Study of PARP Inhibition as Potential Preventative of Brain Injury,Following Stroke 3First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 2First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 3First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 4First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 5First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 6First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 7
Small, removable blades, length 178 mm, (7"). Function: tissue retracting....
... reagents for the quantitative determination of ... as well as heparin- and EDTA- ... using the BN Systems. In acute ... number of plasma proteins, including C-reactive ...
Peapod Rongeur, 5.5 length 140 mm....
Suitable for children and adults. New mechanical design of the skull pin holder and the clamp base ensures improved rigid skull fixation....
Medicine Products: